Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer

Erica Lynn Bradshaw-Pierce, Todd M. Pitts, Aik-Choon Tan, Kelly McPhillips, Mark West, Daniel L. Gustafson, Charles Halsey, Leslie Nguyen, Nathan V. Lee, Julie L C Kan, Brion William Murray, S. Gail Eckhardt

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

P-glycoprotein (P-gp), a member of the ATP-binding cassette transporter family, is overexpressed in a number of different cancers and some studies show that P-gp overexpression can be correlated to poor prognosis or therapeutic resistance. Here we sought to elucidate if PF-3758309 (PF-309), a novel p-21 activated kinase inhibitor, efficacy was influenced by tumor P-gp. Based on in vitro proliferation data, a panel of colorectal cancer cell lines were ranked as sensitive or resistant and ABCB1 (P-gp) expression was evaluated by microarray for these cell lines. P-gp expression was determined by western blot and activity determined by rhodamine efflux assay. Knock down of P-gp and pharmacologic inhibition of P-gp to restore PF-309 activity was performed in vitro. PF-309 activity was evaluated in vivo in cell line xenograft models and in primary patient derived tumor xenografts (PDTX). Mice were treated with 25 mg/kg PF-309 orally, twice daily. On the last day of treatment, tumor and plasma were collected for PF-309 analysis. Here we show that ABCB1 gene expression correlates with resistance to PF-309 treatment in vitro and the expression and activity of P-gp was verified in a panel of resistant cells. Furthermore, inhibition of P-gp increased the sensitivity of resistant cells, resulting in a 4-100-fold decrease in the IC50s. Eleven cell line xenografts and 12 PDTX models were treated with PF-309. From the cell line xenografts, we found a significant correlation between ABCB1 gene expression profiles and tumor response. We evaluated tumor and plasma concentrations for eight tumor models (three cell line xenografts and five PDTX models) and a significant correlation was found between tumor concentration and response. Additionally, we show that tumor concentration is approximately fourfold lower in tumors that express P-gp, verified by western blot. Our in vitro and in vivo data strongly suggests that PF-309 efficacy is influenced by the expression of tumor P-gp.

Original languageEnglish
Article numberArticle 22
JournalFrontiers in Pharmacology
Volume4 MAR
DOIs
Publication statusPublished - 2013 Aug 20
Externally publishedYes

Fingerprint

P-Glycoprotein
Colorectal Neoplasms
Heterografts
Neoplasms
Cell Line
In Vitro Techniques
PF 3758309
Western Blotting
Rhodamines
ATP-Binding Cassette Transporters
Transcriptome
Phosphotransferases
Therapeutics

Keywords

  • Colorectal cancer
  • Intrinsic resistance
  • Mouse xenografts
  • P-glycoprotein
  • Pf-3758309

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Bradshaw-Pierce, E. L., Pitts, T. M., Tan, A-C., McPhillips, K., West, M., Gustafson, D. L., ... Eckhardt, S. G. (2013). Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer. Frontiers in Pharmacology, 4 MAR, [Article 22]. https://doi.org/10.3389/fphar.2013.00022

Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer. / Bradshaw-Pierce, Erica Lynn; Pitts, Todd M.; Tan, Aik-Choon; McPhillips, Kelly; West, Mark; Gustafson, Daniel L.; Halsey, Charles; Nguyen, Leslie; Lee, Nathan V.; Kan, Julie L C; Murray, Brion William; Eckhardt, S. Gail.

In: Frontiers in Pharmacology, Vol. 4 MAR, Article 22, 20.08.2013.

Research output: Contribution to journalArticle

Bradshaw-Pierce, EL, Pitts, TM, Tan, A-C, McPhillips, K, West, M, Gustafson, DL, Halsey, C, Nguyen, L, Lee, NV, Kan, JLC, Murray, BW & Eckhardt, SG 2013, 'Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer', Frontiers in Pharmacology, vol. 4 MAR, Article 22. https://doi.org/10.3389/fphar.2013.00022
Bradshaw-Pierce, Erica Lynn ; Pitts, Todd M. ; Tan, Aik-Choon ; McPhillips, Kelly ; West, Mark ; Gustafson, Daniel L. ; Halsey, Charles ; Nguyen, Leslie ; Lee, Nathan V. ; Kan, Julie L C ; Murray, Brion William ; Eckhardt, S. Gail. / Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer. In: Frontiers in Pharmacology. 2013 ; Vol. 4 MAR.
@article{ac8b6556306743d3bf2149dac06a9bec,
title = "Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer",
abstract = "P-glycoprotein (P-gp), a member of the ATP-binding cassette transporter family, is overexpressed in a number of different cancers and some studies show that P-gp overexpression can be correlated to poor prognosis or therapeutic resistance. Here we sought to elucidate if PF-3758309 (PF-309), a novel p-21 activated kinase inhibitor, efficacy was influenced by tumor P-gp. Based on in vitro proliferation data, a panel of colorectal cancer cell lines were ranked as sensitive or resistant and ABCB1 (P-gp) expression was evaluated by microarray for these cell lines. P-gp expression was determined by western blot and activity determined by rhodamine efflux assay. Knock down of P-gp and pharmacologic inhibition of P-gp to restore PF-309 activity was performed in vitro. PF-309 activity was evaluated in vivo in cell line xenograft models and in primary patient derived tumor xenografts (PDTX). Mice were treated with 25 mg/kg PF-309 orally, twice daily. On the last day of treatment, tumor and plasma were collected for PF-309 analysis. Here we show that ABCB1 gene expression correlates with resistance to PF-309 treatment in vitro and the expression and activity of P-gp was verified in a panel of resistant cells. Furthermore, inhibition of P-gp increased the sensitivity of resistant cells, resulting in a 4-100-fold decrease in the IC50s. Eleven cell line xenografts and 12 PDTX models were treated with PF-309. From the cell line xenografts, we found a significant correlation between ABCB1 gene expression profiles and tumor response. We evaluated tumor and plasma concentrations for eight tumor models (three cell line xenografts and five PDTX models) and a significant correlation was found between tumor concentration and response. Additionally, we show that tumor concentration is approximately fourfold lower in tumors that express P-gp, verified by western blot. Our in vitro and in vivo data strongly suggests that PF-309 efficacy is influenced by the expression of tumor P-gp.",
keywords = "Colorectal cancer, Intrinsic resistance, Mouse xenografts, P-glycoprotein, Pf-3758309",
author = "Bradshaw-Pierce, {Erica Lynn} and Pitts, {Todd M.} and Aik-Choon Tan and Kelly McPhillips and Mark West and Gustafson, {Daniel L.} and Charles Halsey and Leslie Nguyen and Lee, {Nathan V.} and Kan, {Julie L C} and Murray, {Brion William} and Eckhardt, {S. Gail}",
year = "2013",
month = "8",
day = "20",
doi = "10.3389/fphar.2013.00022",
language = "English",
volume = "4 MAR",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer

AU - Bradshaw-Pierce, Erica Lynn

AU - Pitts, Todd M.

AU - Tan, Aik-Choon

AU - McPhillips, Kelly

AU - West, Mark

AU - Gustafson, Daniel L.

AU - Halsey, Charles

AU - Nguyen, Leslie

AU - Lee, Nathan V.

AU - Kan, Julie L C

AU - Murray, Brion William

AU - Eckhardt, S. Gail

PY - 2013/8/20

Y1 - 2013/8/20

N2 - P-glycoprotein (P-gp), a member of the ATP-binding cassette transporter family, is overexpressed in a number of different cancers and some studies show that P-gp overexpression can be correlated to poor prognosis or therapeutic resistance. Here we sought to elucidate if PF-3758309 (PF-309), a novel p-21 activated kinase inhibitor, efficacy was influenced by tumor P-gp. Based on in vitro proliferation data, a panel of colorectal cancer cell lines were ranked as sensitive or resistant and ABCB1 (P-gp) expression was evaluated by microarray for these cell lines. P-gp expression was determined by western blot and activity determined by rhodamine efflux assay. Knock down of P-gp and pharmacologic inhibition of P-gp to restore PF-309 activity was performed in vitro. PF-309 activity was evaluated in vivo in cell line xenograft models and in primary patient derived tumor xenografts (PDTX). Mice were treated with 25 mg/kg PF-309 orally, twice daily. On the last day of treatment, tumor and plasma were collected for PF-309 analysis. Here we show that ABCB1 gene expression correlates with resistance to PF-309 treatment in vitro and the expression and activity of P-gp was verified in a panel of resistant cells. Furthermore, inhibition of P-gp increased the sensitivity of resistant cells, resulting in a 4-100-fold decrease in the IC50s. Eleven cell line xenografts and 12 PDTX models were treated with PF-309. From the cell line xenografts, we found a significant correlation between ABCB1 gene expression profiles and tumor response. We evaluated tumor and plasma concentrations for eight tumor models (three cell line xenografts and five PDTX models) and a significant correlation was found between tumor concentration and response. Additionally, we show that tumor concentration is approximately fourfold lower in tumors that express P-gp, verified by western blot. Our in vitro and in vivo data strongly suggests that PF-309 efficacy is influenced by the expression of tumor P-gp.

AB - P-glycoprotein (P-gp), a member of the ATP-binding cassette transporter family, is overexpressed in a number of different cancers and some studies show that P-gp overexpression can be correlated to poor prognosis or therapeutic resistance. Here we sought to elucidate if PF-3758309 (PF-309), a novel p-21 activated kinase inhibitor, efficacy was influenced by tumor P-gp. Based on in vitro proliferation data, a panel of colorectal cancer cell lines were ranked as sensitive or resistant and ABCB1 (P-gp) expression was evaluated by microarray for these cell lines. P-gp expression was determined by western blot and activity determined by rhodamine efflux assay. Knock down of P-gp and pharmacologic inhibition of P-gp to restore PF-309 activity was performed in vitro. PF-309 activity was evaluated in vivo in cell line xenograft models and in primary patient derived tumor xenografts (PDTX). Mice were treated with 25 mg/kg PF-309 orally, twice daily. On the last day of treatment, tumor and plasma were collected for PF-309 analysis. Here we show that ABCB1 gene expression correlates with resistance to PF-309 treatment in vitro and the expression and activity of P-gp was verified in a panel of resistant cells. Furthermore, inhibition of P-gp increased the sensitivity of resistant cells, resulting in a 4-100-fold decrease in the IC50s. Eleven cell line xenografts and 12 PDTX models were treated with PF-309. From the cell line xenografts, we found a significant correlation between ABCB1 gene expression profiles and tumor response. We evaluated tumor and plasma concentrations for eight tumor models (three cell line xenografts and five PDTX models) and a significant correlation was found between tumor concentration and response. Additionally, we show that tumor concentration is approximately fourfold lower in tumors that express P-gp, verified by western blot. Our in vitro and in vivo data strongly suggests that PF-309 efficacy is influenced by the expression of tumor P-gp.

KW - Colorectal cancer

KW - Intrinsic resistance

KW - Mouse xenografts

KW - P-glycoprotein

KW - Pf-3758309

UR - http://www.scopus.com/inward/record.url?scp=84881501082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881501082&partnerID=8YFLogxK

U2 - 10.3389/fphar.2013.00022

DO - 10.3389/fphar.2013.00022

M3 - Article

C2 - 23524533

AN - SCOPUS:84881501082

VL - 4 MAR

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - Article 22

ER -